Associazione Volontari Pazienti Oncologici
Quick facts
Phase 3 pipeline
- RT+CDDP/5-FU · Oncology
RT+CDDP/5-FU is a combination chemotherapy regimen that works by inhibiting DNA replication and interfering with DNA repair, ultimately leading to cell death. - RT+CETUXIMAB · Oncology
RT+CETUXIMAB combines radiation therapy with cetuximab, an EGFR-blocking monoclonal antibody, to inhibit tumor cell growth and enhance radiosensitivity.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Associazione Volontari Pazienti Oncologici portfolio CI brief
- Associazione Volontari Pazienti Oncologici pipeline updates RSS
Frequently asked questions about Associazione Volontari Pazienti Oncologici
What is Associazione Volontari Pazienti Oncologici's pipeline?
Associazione Volontari Pazienti Oncologici has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include RT+CDDP/5-FU, RT+CETUXIMAB.
Related
- Sector hub: All tracked pharma companies